News

Analysts Maintain Positive Outlook on FactSet's Earnings Growth

Analysts Maintain Positive Outlook on FactSet's Earnings Growth

Analysts Keep Positive View on FactSet's Earnings Growth

BMO Capital has reaffirmed its Market Perform rating for FactSet Research Systems (NYSE:FDS), maintaining a price target of $440.00. Their analysis pointed out that FactSet's latest earnings report featured an adjusted earnings per share (EPS) that outperformed expectations, thanks to impressive margins.

Looking at the year-over-year performance, the company showed stability with an organic revenue increase of about 5%. However, its organic Annual Subscription Value (ASV) growth rate did show a slight deceleration.

In an important update, FactSet has issued its first outlook for the fiscal year 2025, which aligns with the upper end of consensus estimates. Additionally, the company announced an investor day scheduled for November, offering stakeholders an excellent chance to gain insights into its strategic plans and overall performance.

Following the earnings report, shares of FactSet Research Systems experienced positive movement in pre-market trading. This market reaction suggests a favorable interpretation of the company’s performance and the investor day announcement, as indicated by the stock’s pre-open activity.

As the investor day approaches, both investors and analysts are eager to hear more about the company’s future strategies. It’s worth noting that FactSet won’t be updating any of its forecasts until its first-quarter earnings for the fiscal year 2025 are released.

FactSet recently reported strong fourth-quarter results that exceeded analyst expectations. Its adjusted EPS reached $3.74, surpassing the $3.62 consensus, while revenue grew by 4.9% year-over-year, totaling $562.2 million—again exceeding the expected $546.76 million.

The company's ability to maintain strong operating margins was clear, as FactSet’s adjusted operating margin increased to 35.8%, up from 33.4% the prior year, driven primarily by lower compensation costs.

On a different note, Wolfe Research has issued an underperform rating for FactSet shares. This stems from concerns about management’s commentary on revenue growth projections and the various factors affecting year-over-year margin trends.

Despite this, Wolfe Research did indicate that FactSet’s client and user base has grown compared to the fourth fiscal quarter of 2023, hinting at an improving demand landscape for the company’s services.

FactSet's earnings guidance for fiscal 2025 stands at $16.80-$17.40 per share, which is slightly different from the Wall Street average of $17.36. Notably, the company's revenue forecast of $2.29-$2.31 billion aligns well with the consensus estimate of $2.30 billion, reinforcing its resilient performance in the face of market fluctuations.

InvestingPro Insights

If you’re interested in examining FactSet Research Systems’ financial position, InvestingPro offers real-time insights. The company has a solid market capitalization of $17.0 billion, along with a P/E ratio of 33.36, suggesting a premium valuation.

It's also worth noting its PEG ratio of 17.74, which indicates the premium being paid for growth relative to its current earnings. Despite this high valuation, FactSet has shown a strong commitment to returning value to shareholders by increasing its dividend for 26 consecutive years, resulting in a current dividend yield of 0.93%.

The company continues to demonstrate strong revenue growth, achieving a 6.23% year-over-year increase as of Q3 2024, which supports the positive trends observed in its recent earnings report. Moreover, FactSet’s gross profit margin stands at an impressive 53.26%, showing the company’s capability to thrive while expanding its market presence.

Experts point out that while FactSet's current trading metrics show a high earnings multiple and elevated P/E ratio compared to short-term earnings growth, its historical performance has yielded solid returns over the last decade. This track record may be attractive to long-term investors weighing the company's future prospects.

This article was generated with AI assistance and has been reviewed for accuracy. For additional details, please refer to the terms and conditions.

Frequently Asked Questions

What is the current stock target for FactSet?

The current stock target for FactSet Research Systems (NYSE:FDS) is set at $440.00 by BMO Capital.

How did FactSet perform in its recent earnings report?

FactSet reported an adjusted earnings per share of $3.74, which exceeded analyst expectations, along with a revenue total of $562.2 million, surpassing forecasts.

What are FactSet's revenue growth expectations for fiscal 2025?

For fiscal 2025, FactSet expects its revenue to fall between $2.29 billion and $2.31 billion, closely aligning with industry consensus.

When is FactSet’s upcoming investor day scheduled?

The investor day for FactSet Research Systems is scheduled for November 14, 2024.

How has FactSet's dividend policy contributed to its appeal?

FactSet has increased its dividend for 26 consecutive years, highlighting its dedication to returning value to shareholders, which translates to a dividend yield of 0.93%.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 229

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 393

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 346

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 174

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 162

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 223

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 384

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 379

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 317

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 150

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading

Top 5 Most Recently Viewed Articles

BUBBA® and Major League Fishing® Revolutionize Tournament Fishing

Updated Category News Views 164

BUBBA® and Major League Fishing® Transform Tournament Fishing BUBBA App to Exclusively Launch MLF SCORETRACKER LIVE Beginning Spring 2026 BUBBA, a prominent fishing brand recognized for its innovative fishing tools, and Major League Fishing (MLF), the largest tournament-fishing organization globally, are joining forces to launch a revolutionary feature within the BUBBA...

Continue Reading
Skin Tech's RRS® HA Long Lasting Wins AMWC 2026 Honor

Updated Category News Views 14

A Breakthrough in Aesthetic Medicine Skin Tech Pharma Group has hit a home run with RRS® HA Long Lasting, bagging the title of Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026. This ain't your average trophy—it’s akin to the Oscars of aesthetic medicine. The fact that this recognition comes from such a prestigious setting...

Continue Reading
Medtronic Expands MiniMed 780G System for Diabetes Management

Updated Category News Views 304

Medtronic's FDA Milestone with MiniMed™ 780G System Medtronic plc (NYSE: MDT), a leader in healthcare technology, recently reached significant regulatory milestones with the U.S. Food and Drug Administration (FDA) regarding its MiniMed™ 780G system. These milestones include the clearance of the SmartGuard™ algorithm as an interoperable automated glycemic controller...

Continue Reading
Innovative Shipping Solution Revolutionizes Ecommerce Operations

Updated Category News Views 120

Saltbox Launches Parsel for Ecommerce Growth Saltbox, recognized for its innovative warehousing and logistics solutions, is unveiling a new shipping platform called Parsel. This platform is specifically designed to meet the fast-changing needs of growing ecommerce businesses. By integrating effortlessly with major ecommerce platforms, Parsel boosts the operational...

Continue Reading
Exploring the Rapid Growth of the Satellite Bus Market

Updated Category News Views 99

Exploring the Satellite Bus Market's Growth Potential The Satellite Bus Market is on the verge of remarkable expansion, with its valuation projected to rise from USD 13.6 billion in 2023 to an impressive USD 25 billion by the end of 2032. The increasing reliance on Earth observation satellites across various fields such as environmental monitoring, agriculture, disaster...

Continue Reading